To join this case, fill out the form below
Dicerna Pharmaceuticals, Inc. Investigation
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Dicerna Pharmaceuticals, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dicerna Pharmaceuticals, Inc. (“Dicerna” or the “Company”) (NASDAQ: DRNA) in connection with the proposed acquisition of the Company by Novo Nordisk.  Under the terms of the merger agreement, the Company’s shareholders will receive $38.25 per share in cash for each share of Dicerna common stock that they hold.  The all-cash transaction is valued at $3.3billion.

WeissLaw LLP is investigating whether (i) Dicerna’s board of directors acted in the best interest of Dicerna’s shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Dicerna’s shareholders, and (iii) whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed.

‍

Other Cases

May 9, 2024

DecisionPoint Systems, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of DecisionPoint Systems, Inc. (“DecisionPoint” or the “Company”) (NYSE: DPSI), in connection with its acquisition by affiliates of Barcoding Holdings, LLC. Under the merger agreement, the Company’s shareholders will receive $10.22 per share.

Join Case →

May 9, 2024

Deciphera Pharmaceuticals, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Deciphera Pharmaceuticals, Inc. (“Deciphera” or the“Company”) (NASDAQ: DCPH), in connection with its acquisition by ONO Pharmaceutical, Co., Ltd. via tender offer. Under the merger agreement, the Company’s shareholders will receive $25.60 per share.

Join Case →

May 9, 2024

U.S. Silica Holdings, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of U.S. Silica Holdings, Inc. (“U.S. Silica” or the “Company”) (NYSE: SLCA), in connection with its acquisition by affiliates of Apollo Global Management, Inc. (NYSE: APO). Under the merger agreement, the Company’s shareholders will receive $15.50 per share. The transaction is valued at approximately $1.85 billion.

Join Case →

Where to find us?

new york

305 Broadway, 7th FI
New York, NY 10007
(212) 682-3025

california

8383 Wilshire Blvd., Suite 935
Beverly Hills, CA 90211
(310) 208-2800

georgia

476 Hardendorf Ave. NE
Atlanta, GA 30307
(404) 692-7910

NEW JERSEY

4 Brighton Rd, Suite. 204
Clifton, NJ 07012

Copyright 2022 Weiss Law. All rights reserved

Attorney AdvertisingLegal

Design by Cramdyn